Phaseline

Companies › Joint Biosciences

Joint Biosciences: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
OVV-01 Injection
oncolytic virus
–Phase 1Advanced Solid TumorsApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07648472OVV-01 InjectionPhase 1Advanced Solid TumorsOncologyApr 2027

From the company's SEC filings

Cash of $18m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.